Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of First Rank Symptoms (FRS) on Schizophrenia

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Sep 11, 2017

Keywords

ClinConnect Summary

Schizophrenia is a common psychiatric disorder that affects approximately 1% of the general population. This disease can be described in three dimensions: disorganization, delusions and negative signs. The "first rank symptoms" (FRS) were first described by Kurt Schneider. These are core symptoms of schizophrenia that were combined to make pathognomonic signs of the disease and remain at the center of many classifications of the disease. These symptoms are voices or thoughts expressed aloud, voices who argue them, voices that comment on behavior or thoughts, delusional perceptions, experien...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Suffering from schizophrenia (according to DSM IV-TR)
• • Presenting FRS at least once a day despite well-conducted antipsychotic treatment, objectified by FRS subscore of the SAPS (items 2, 3 and items 15-19) with at least two FRS listed \> 1 of the corresponding item of the SAPS
• • Being informed of the objectives and constraints of the study and signing the consent form or signing by the guardian
• • Patient having had a preliminary clinical examination
• Exclusion Criteria:
• • Left-lateralized
• • Previously treated with rTMS in the previous 6 month,
• • Contraindications of the rTMS practice: unstabilized epilepsy, presence of foreign eye metallic material, pacemaker, neurostimulator, cochlear implants and in general all medical equipment installed immovably, metal heart valve, vascular clips formerly located on cranial aneurysm
• • Pregnancy or breastfeeding women
• • hospitalization under constraint
• • Subject already involved in another interventional clinical research evaluating schizophrenia treatment
• • patient with severe drug use disorder (excluding coffee and tobacco) according to the DSM-5 criteria